Navigation Links
New Vaccine May Help Type 1 Diabetics in Future
Date:10/8/2008

Early study finds it appears to sustain insulin production in the newly diagnosed.

WEDNESDAY, Oct. 8 (HealthDay News) -- Swedish researchers have developed a vaccine that may change the way the immune system responds in people who are newly diagnosed with type 1 diabetes.

"By a very simple vaccination, without adverse events, it seems possible to save [a person's] own insulin secretion, which may be extremely important for diabetic children and adolescents," said the study's lead author, Dr. Johnny Ludvigsson, a professor of pediatrics and head physician at Linkoping University Hospital.

However, the results of this preliminary study didn't change the clinical course of the disease for the study participants. Insulin requirements of children involved in the study were similar whether the children were treated with the new vaccine or received a placebo.

Results of the study were released Wednesday online by the New England Journal of Medicine, and will be published in its Oct. 30 issue.

Type 1 diabetes is believed to be an autoimmune disease in which the body's immune system mistakenly attacks itself. In type 1 diabetes, "insulin-producing cells are killed by their own immune system in a 'civil war,' " said Ludvigsson. This civil war leads to a lack of insulin in the body, and insulin is a key hormone that allows the body to metabolize carbohydrates and sugar from foods. Without replacement insulin, people with type 1 diabetes would die. Even with treatment, there are numerous complications that can occur, including damage to the kidneys, eyes, heart and nerves.

Past research on interrupting an immune system gone awry has focused on drugs that suppress the immune system, like those used for people receiving transplants or being treated for cancer. Although researchers did have some success in slowing or stopping early-onset diabetes, that success came at a cost.

"Many drugs caused severe toxic side effects," said Dr. Denise Faustman, director of immunobiology at Massachusetts General Hospital in Boston, and the author of an accompanying editorial in the journal. "With a big immune suppressant, you can change the amount of insulin kids take, sometimes you can even make them insulin-free for awhile, but you may cause kidney damage. The ratio of toxicity versus benefit wasn't there."

The new vaccine treatment under study focuses on the immune response, rather than trying to blunt the entire immune system. It's made of a protein called GAD that's normally found in the brain and in the insulin-producing islet cells of the pancreas. In people with diabetes, it's as if they're allergic to GAD, Ludvigsson explained.

The hope is that the vaccine he and his team developed -- which was administered the first day of the study and then again at day 30 -- will work in a similar manner to allergy immunotherapy and help the body learn to tolerate GAD again.

The study included 70 children between the ages of 10 and 18 who had been diagnosed with type 1 diabetes no more than 18 months before the start of the study. The children were randomly split into two groups -- one received treatment, the other a placebo.

At the end of the study, insulin requirements didn't change. But, in children who were more recently diagnosed, there was evidence that the treated group retained more activity in their pancreas, Ludvigsson said.

That's important because the more insulin-producing function you retain, "the short-term risks are less, as are the risk of long-term complications," said Dr. Richard Insel, executive vice president of research for the Juvenile Diabetes Research Foundation.

"What you're seeing is, the field is trying to move away from broad-based immunosuppression to targeting one specific immune response, and this is an early attempt to develop a much more focused approach to modulate immune function in new-onset diabetes," Insel said.

The good news is that the vaccine seemed safe and didn't cause any troubling side effects, according to Faustman. "GAD looks pretty benign here -- two vaccinations given four weeks apart. There's something positive happening, though the therapeutic benefit is small. But, there was a measurable and significant benefit."

Ludvigsson said the researchers have begun new trials, including children who've had diabetes for a much shorter time because those were the ones who responded most in this study. Additionally, they'll be working on a clinical trial to see if this vaccination could be used to prevent type 1 diabetes from occurring in children who have a high risk of the disease.

More information

Learn more about type 1 diabetes from the U.S. National Library of Medicine.



SOURCES: Johnny Ludvigsson, M.D., Ph.D., professor of pediatrics, and head physician, Linkoping University Hospital, Sweden; Denise L. Faustman, M.D., Ph.D., director, immunobiology, Massachusetts General Hospital, and associate professor of medicine, Harvard Medical School, Boston; Richard Insel, M.D., executive vice president, Juvenile Diabetes Research Foundation; Oct. 30, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State College of Optometry won ... on visual evoked potential and human attention. The article, VEP and Human Attention: ... NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to ...
(Date:5/25/2016)... TX (PRWEB) , ... May 25, 2016 , ... ... the United States, named Dr. Anh Tat Nguyen, as the Medical Director of its ... the facility Medical Director of our new DeSoto location,” said Dr. James M. Muzzarelli, ...
(Date:5/25/2016)... New Jersey (PRWEB) , ... May 25, 2016 , ... ... specialized technology firm will be selling the device branded as Stern’s Real Time ... is geared to bedbugs to the hotel and motel industry, colleges for use in ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... According to ... that a group of people randomly assigned to reduce the amount of calories they ... 12 percent drop in body weight enjoyed better sleep, improved quality of life, and ...
(Date:5/24/2016)... ... 24, 2016 , ... BTC Media, a leading digital currency ... to be held in Nashville, Tennessee on September 7, 2016. , The conference ... the event will host teams from around the world, competing to build the ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
(Date:5/23/2016)... Conn. , May 23, 2016   ... has entered into an agreement with Egalet Corporation ... patent claims. As part of the agreement the ... and will enable all three companies to develop ... properties. "This agreement reflects the commitment ...
Breaking Medicine Technology: